Welcome Guest
Home > Clinical Breast Cancer > Volume 7 |  Issue 7 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Kaufmann M, Smith R, von Minckwitz G, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-2608.
    2.  Anderson S, Bear HD, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174.
    3.  Ditsch N, Konency G, Untch M, et al. Dose-dense sequential epiru-bicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc Am Soc Clin Oncol 2002; 21:31a-31a.
    4.  Caputo A, Raab G, von Minckwitz G, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676-2685.
    5.  Mamounas E, Wang J, Wolmark N, et al. Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001:96-102.
    6.  Llombart-Cussac A, Rowland K, Theodoulou M, et al. A phase II trial of pemetrexed disodium (ALIMTA(tm), LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy). Breast Cancer Res Treat 2000; 64:122-122.
    7.  Martin M, Namer M, Spielmann M, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003; 14:1246-1252.
    8.  Coleman RE, Miles DW, Smith IE, et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 2001; 37:1366-1371.
    9.  Blum JL, Clark RS, O'Shaughnessy JA, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005; 6:143-149.
    10.  Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12:832-838.
    11.  He YD, Van de Vijver MJ, van't Veer LJ, van’ t Veer L, Van’ t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
    12.  Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003; 98:1150-1160.
    13.  Bryant J, Fisher B, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
    14.  Julien JP, van de Velde CJ, Van de Velde CJH, van der Hage JA, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-4237.
    15.  Schneeweiss A, Thuerigen O, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24:1839-1845.
    16.  Arbuck SG, Eisenhauer EA, Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
    17.  Ittrich C, Schlingemann J, Thuerigen O, et al. Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays. Nucleic Acids Res 2005; 33:e29-e29.
    18.  Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume 7
  •  Issue 7
    • Publication Date: April 2007


Doxorubicin/Pemetrexed Followed by Docetaxel Versus Doxorubicin/Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early-Stage Breast Cancer: A Randomized Phase II Trial


Andreas Schneeweiss, Ilka Lauschner, Amparo Ruiz, Angel Guerrero, Pedro Sánchez-Rovira, Miguel Angel Seguí, Kay Goerke, Michael Wolf, Alexey G. Manikhas, Juergen Wacker, Frederik Marmé, Peter Lichter, Hans-Peter Sinn, Christof Sohn, Kambiz Mansouri, Thomas Bauknecht, Meinhard Hahn

Background: Microarray gene expression profiling has indicated that complex molecular gene expression signatures might be predictive of outcome after systemic treatment for early breast cancer. Neoadjuvant systemic therapy (NST) with its assessment of pathologic complete response (pCR), so far the best surrogate parameter for cure, provides a unique opportunity to rapidly identify such molecular predictors. Patients and Methods: Currently, an international, randomized phase II study of 2 sequential regimens as NST is being conducted in patients with primary invasive breast cancer T2-4a-c N0-2 M0. Patients receive 4 cycles of doxorubicin/pemetrexed, followed by 4 cycles of docetaxel (AP-Doc) or 4 cycles of doxorubicin/cyclophosphamide, followed by 4 cycles of docetaxel (AC-Doc). Tumor, tissue, blood, and serum are collected at baseline and, if available, after 4 cycles of chemotherapy, and at surgery. The clinical objectives are to assess pCR rate, tumor response, rate of histologically negative axillary lymph nodes, disease-free survival, and safety after NST with AP-Doc or AC-Doc. Translational research objectives include the identification of differentially expressed genes predictive for the achievement of pCR after either treatment regimen. Results: As of January 2007, 178 of the 256 patients planned for this study had been enrolled at 12 European centers. The recommendation after a planned interim safety and efficacy analysis was to continue with the trial as planned. Conclusion: We anticipate this study will provide a better understanding of the treatment options with pemetrexed in primary breast cancer and give insight into the practical robustness of the new marker sets in response prediction.

Key words: Gene expression signature, Pathologic complete response, Prediction of response and resistance


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. KELUARAN SGP
  2. TOGEL